Lexaria Bioscience Future Growth
Future criteria checks 2/6
Lexaria Bioscience is forecast to grow earnings and revenue by 23.1% and 75.9% per annum respectively while EPS is expected to grow by 30.6% per annum.
Key information
23.1%
Earnings growth rate
30.6%
EPS growth rate
Pharmaceuticals earnings growth | 23.5% |
Revenue growth rate | 75.9% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 29 Apr 2024 |
Recent future growth updates
Recent updates
Lexaria Bioscience gets third patent granted in Japan
Jul 14Lexaria Bioscience's DehydraTECH licensee Cannadips expands internationally
Jul 07Is Lexaria Bioscience (NASDAQ:LEXX) In A Good Position To Deliver On Growth Plans?
Apr 15We Think Lexaria Bioscience (NASDAQ:LEXX) Can Afford To Drive Business Growth
Dec 07Lexaria Hits New 52-Week High With Positive Data On Enhanced Treatment For COVID-19
Jul 22Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
8/31/2026 | 1 | -9 | N/A | N/A | 2 |
8/31/2025 | 0 | -7 | N/A | N/A | 2 |
8/31/2024 | 1 | -5 | N/A | N/A | 1 |
2/29/2024 | 0 | -5 | -5 | -5 | N/A |
11/30/2023 | 0 | -6 | -6 | -6 | N/A |
8/31/2023 | 0 | -7 | -6 | -6 | N/A |
5/31/2023 | 0 | -7 | -6 | -5 | N/A |
2/28/2023 | 0 | -7 | -5 | -5 | N/A |
11/30/2022 | 0 | -7 | -5 | -5 | N/A |
8/31/2022 | 0 | -7 | -5 | -5 | N/A |
5/31/2022 | 0 | -7 | -5 | -5 | N/A |
2/28/2022 | 0 | -7 | -5 | -5 | N/A |
11/30/2021 | 0 | -7 | -5 | -4 | N/A |
8/31/2021 | 1 | -6 | -4 | -4 | N/A |
5/31/2021 | 1 | -5 | -4 | -3 | N/A |
2/28/2021 | 1 | -4 | -3 | -3 | N/A |
11/30/2020 | 1 | -4 | -3 | -3 | N/A |
8/31/2020 | 0 | -4 | -3 | -3 | N/A |
5/31/2020 | 0 | -4 | -3 | -3 | N/A |
2/29/2020 | 0 | -4 | -3 | -3 | N/A |
11/30/2019 | 0 | -4 | -4 | -3 | N/A |
8/31/2019 | 0 | -4 | -4 | -3 | N/A |
5/31/2019 | 0 | -4 | -4 | -3 | N/A |
2/28/2019 | 0 | -6 | -3 | -3 | N/A |
11/30/2018 | 0 | -7 | -3 | -3 | N/A |
8/31/2018 | 0 | -7 | -3 | -3 | N/A |
5/31/2018 | 0 | -6 | -2 | -2 | N/A |
2/28/2018 | 0 | -3 | -2 | -2 | N/A |
11/30/2017 | 0 | -2 | N/A | -2 | N/A |
8/31/2017 | 0 | -2 | N/A | -2 | N/A |
5/31/2017 | 0 | -1 | N/A | -1 | N/A |
2/28/2017 | 0 | -1 | N/A | -1 | N/A |
11/30/2016 | 0 | -1 | N/A | -1 | N/A |
8/31/2016 | 0 | -1 | N/A | -1 | N/A |
5/31/2016 | 0 | -1 | N/A | -1 | N/A |
2/29/2016 | 0 | -2 | N/A | -1 | N/A |
11/30/2015 | 0 | -2 | N/A | -2 | N/A |
8/31/2015 | 0 | -2 | N/A | -2 | N/A |
5/31/2015 | 0 | -2 | N/A | -1 | N/A |
2/28/2015 | 0 | -2 | N/A | -1 | N/A |
11/30/2014 | N/A | -2 | N/A | -1 | N/A |
8/31/2014 | N/A | -2 | N/A | -1 | N/A |
7/31/2014 | 1 | -1 | N/A | 0 | N/A |
4/30/2014 | 1 | -1 | N/A | 0 | N/A |
1/31/2014 | 1 | 0 | N/A | 0 | N/A |
10/31/2013 | N/A | -1 | N/A | 0 | N/A |
7/31/2013 | 1 | 0 | N/A | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LEXX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LEXX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LEXX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LEXX's revenue (75.9% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: LEXX's revenue (75.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LEXX's Return on Equity is forecast to be high in 3 years time